Clinical Trial Update: SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

View source ↗

Summary

Pfizer's RSV vaccine Abrysvo is being studied in adults aged 60 and older, and the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ABRYSVO

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus Infection | Status: ACTIVE_NOT_RECRUITING